Towards an AIDS vaccine: The transmembrane envelope protein as target for broadly neutralizing antibodies

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 4-9

  Denner, Joachim ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

AIDS; Neutralizing antibodies; Retroviruses; Transmembrane envelope proteins

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; TRANSMEMBRANE ENVELOPE PROTEIN; UNCLASSIFIED DRUG;

AIDS PATIENT; ANTIGEN BINDING; DRUG MECHANISM; FELINE LEUKEMIA VIRUS; FUSION PEPTIDE PROXIMAL REGION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; MEMBRANE PROXIMAL EXTERNAL REGION; NONHUMAN; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; GAMMARETROVIRUS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HUMANS;

EID: 79551680990     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14555     Document Type: Review

References (68)

1. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93:681-4. (Pubitemid 28257575)
2. Tailor CS, Lavillette D, Marin M, Kabat D. Cell surface receptors for gammaretroviruses. Curr Top Microbiol Immunol 2003; 281:29-106. (Pubitemid 36950683)
3. Melikyan GB. Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 2008; 10:5-111.
4. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-9.
5. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007;13:1032-4. (Pubitemid 47517505)
6. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-through-put neutralization assay together with an analytical selection algorithm. J Virol 2009; 83:7337-48.
7. Kwong PD,Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-59. (Pubitemid 28289647)
8. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010; 84:1631-6.
9. Dey B, Pancera M, Svehla K, Shu Y, Xiang SH, Vainshtein J, et al. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics and immunogenicity. J Virol 2007; 81:5579-93. (Pubitemid 46846998)
10. Gnann JW Jr, Nelson JA, Oldstone MB. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol 1987; 61:2639-41. (Pubitemid 17097580)
11. Denner J, Norley S, Kurth R. The immunosuppressive peptide of HIV-1: functional domains and immune response in AIDS patients. AIDS 1994; 23:1063-72. (Pubitemid 24228701)
12. Pietzsch J, Scheid JF, Mouquet H, Seaman MS, Broder CC, Nussenzweig MC. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol 2010; 84:5032-42.
13. Golding H, Zaitseva M, de Rosny E, King LR, Manischewitz J, Sidorov I, et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 2002; 76:6780-90. (Pubitemid 34633544)
14. Opalka D, Pessi A, Bianchi E, Ciliberto G, Schleif W, McElhaugh M, et al. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods 2004; 287:49-65. (Pubitemid 38510208)
15. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10:11-23.
16. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994; 10:359-69. (Pubitemid 24141210)
17. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-7. (Pubitemid 23309131)
18. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17:1757-65. (Pubitemid 34114213)
19. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glyco-protein gp41. J Virol 2001; 75:10892-905. (Pubitemid 33034579)
20. Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, et al. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5 and 4E10. J Virol 2004; 78:14039-42. (Pubitemid 39612800)
21. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-52. (Pubitemid 39507829)
22. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-905. (Pubitemid 33034579)
23. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003; 17:301-9. (Pubitemid 36223254)
24. Ruprecht RM, Ferrantelli F, Kitabwalla M, Xu W, McClure HM. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine 2003; 21:3370-3. (Pubitemid 36792088)
25. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Koller U, Jilch R, et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004; 54:915-20. (Pubitemid 39529987)
26. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005;11:615-22. (Pubitemid 40868301)
27. Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, Parren PW, et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 2004; 78:3155-61. (Pubitemid 38314375)
28. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H. Characterization of molecular features, antigen-binding and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 2004; 20:755-62. (Pubitemid 39037507)
29. Haynes BF, Fleming J, St. Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-8. (Pubitemid 40941873)
30. Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM, et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 2010; 107:181-6.
31. Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009; 23:2069-77.
32. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009;83:1045-59.
33. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-40.
34. Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, et al. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 2009; 83:11265-74.
35. Haynes BF, Montefiori DC. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 2006; 5:347-63. (Pubitemid 44167156)
36. McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, et al. Progress towards the development of a HIV-1 gp41-directed vaccine. Curr HIV Res 2004; 2:193-204. (Pubitemid 38854931)
37. Hinz A, Schoehn G, Quendler H, Hulsik DL, Stiegler G, Katinger H, et al. Characterization of a trimeric MPER containing HIV-1 gp41 antigen. Virology 2009; 390:221-7.
38. Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, Finotto M, et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci USA 2010; 107:10655-60.
39. Ho J, Uger RA, Zwick MB, Luscher MA, Barber BH, MacDonald KS. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 2005; 23:1559-73. (Pubitemid 40203393)
40. Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, Citron MP, et al. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 2002;277:45811-20. (Pubitemid 35417559)
41. McGaughey GB, Citron M, Danzeisen RC, Freidinger RM, Garsky VM, Hurni WM, et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 2003; 42:3214-23. (Pubitemid 36348629)
42. Zwick MB. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS 2005; 19:1725-37. (Pubitemid 41546591)
43. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005; 79:1252-61. (Pubitemid 40053907)
44. Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, et al. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction and potential for regulation in acute infection. J Virol 2008; 82:115-5.
45. Moreno MR, Giudici M, Villalaín J. The membrano-tropic regions of the endo and ecto domains of HIV gp41 envelope glycoprotein. Biochim Biophys Acta 2006; 1758:111-23.
46. Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, Song L, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008; 28:52-63.
47. Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, et al. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008; 373:72-84.
48. Fiebig U, Stephan O, Kurth R, Denner J. Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation? Virology 2003; 307:406-13. (Pubitemid 36344171)
49. Langhammer S, Fiebig U, Kurth R, Denner J. Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine 2005;23:3341-8. (Pubitemid 40523129)
50. Langhammer S, Hübner J, Jarrett O, Kurth R, Denner J. Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: Absence of antigenemia following challenge. Antiviral Res, 2011; 89:119-123.
51. Langhammer S, Hübner J, Kurth R, Denner J. Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. Immunology 2006; 117:229-37.
52. Langhammer S, Fiebig U, Hübner J, Kurth R, Denner J. Increased neutralizing antibody response after simultaneous immunization with Leucogen and the feline leukemia virus transmembrane protein. Intervirology 2010; 54:78-86.
53. Fiebig U, Hartmann MG, Bannert N, Kurth R, Denner J. Transspecies transmission of the endogenous koala retrovirus. J Virol 2006; 80:5651-4.
54. Fiebig U, Eschricht M, Schmolke M, Kurth R, Denner J. Mode of interaction between the HIV-1 neutralizing monoclonal antibody 2F5 and its epitope. AIDS 2009;23:887-95.
55. Fiebig U, Schmolke M, Karlas A, Kurth R, Denner J. Induction of anti-viral neutralising antibodies. World Intellectual Property Organisation patent 2005; WO 2005/021574.
56. Bellamy-McIntyre AK, Lay CS, Baär S, Maerz AL, Talbo GH, Drummer HE, et al. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem 2007; 282:23104-16. (Pubitemid 47311910)
57. Noah E, Biron Z, Naider F, Arshava B, Anglister J. The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide. Biochemistry 2008; 47:6782-92. (Pubitemid 351898933)
58. Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog 2010; 6:1000880.
59. Hager-Braun C, Katinger H, Tomer KB. The HIVneutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen. J Immunol 2006; 176:7471-81. (Pubitemid 43849050)
60. Lorizate M, Gómara MJ, de la Torre BG, Andreu D, Nieva JL. Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex. J Mol Biol 2006; 360:45-55. (Pubitemid 43927809)
61. Geonnotti AR, Bilska M, Yuan X, Ochsenbauer C, Edmonds TG, Kappes JC, et al. Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin- mediated chemokine and gamma interferon production. AIDS Res Hum Retroviruses 2010; 26:279-91.
62. Denner J. Immunosuppression by oncogenic retroviridae In: Zschiesche W, ed. Immune modulation by infectious agents. Fischer Verlag, Jena 1987; 114-201.
63. Oostendorp RAJ, Meijer CJLM, Scheper RJ. Immunosuppression by retroviral-envelope-related proteins and their role in non-retroviral disease. Crit Rev Oncol Hematol 1993; 14:189-206. (Pubitemid 23275438)
64. Denner J. Immunosuppression by retroviruses: implications for xenotransplantation. Ann NY Acad Sci 1998;862:75-86. (Pubitemid 29044014)
65. Denner J. How does HIV induce AIDS? The virus protein hypothesis. J Hum Virol 2000; 3:81-2. (Pubitemid 30463674)
66. Denner J. Endogenous retroviruses. In: Kurth R, Bannert N, eds. Retroviruses: Molecular Biology, Genomics and Pathogenesis, Caister Academic Press, Hethersett, Norwich 2010; 35-69.
67. Schlecht-Louf G, Renard M, Mangeney M, Letzelter C, Richaud A, Ducos B, et al. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci USA 2010; 107:3782-7.
68. Mangeney M, Renard M, Schlecht-Louf G, Bouallaga I, Heidmann O, Letzelter C, et al. Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proc Natl Acad Sci USA 2007; 104:20534-9.